Using FAPI PET/MRI to Evaluate Prostate Cancer
Novel FAP-targeted Approach to Imaging Patients With or High-risk for Metastatic Prostate Cancer
University of Wisconsin, Madison
30 participants
Feb 27, 2026
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer. Participants will undergo two PET/MRI scans during two research visits, each of which may last up to 2.5 hours.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
5 +/- 2 mCi of Ga-FAPI-46
Undergo PET scan
Undergo MRI scan
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06675357